Tavipec

Tavipek belongs to a pharmacotherapeutic group of drugs that act on the respiratory system and have expectorant properties. Tavipek belongs to a group of drugs that are used for coughs and colds. The drug can be used as an auxiliary agent in combination with other drugs to treat similar problems.

Indications Tavipec

Indications for the use of the drug Tavipek are considered to be the presence of symptoms of diseases of the upper and lower respiratory tract in the patient, which are accompanied by a cough - sinusitis, acute, chronic and emphysema bronchitis, laryngoronchitis, bronchiolitis, bronchiectasis (as a means of adjuvant therapy), pulmonary emphysema, smoker's cough, bronchial asthma, pulmonary tuberculosis.

The drug is used as one of the means of complex treatment of the above diseases.

Release form

Release form: the drug is produced in soft capsules, soluble in the intestine, with one hundred and fifty mg of the drug in each.

The capsules are produced in a transparent shell made of gelatin; they are oval in shape, yellow in color, and have a visible seam. Each capsule contains a movable transparent uncolored liquid. The liquid inside the capsule may also be light yellow (with some manufacturers - greenish-yellow) in color. The contents of the capsule have a lavender scent.

One capsule contains:

• active substance – lavender oil – one hundred and fifty mg;
• excipients: the capsule shell consists of the following components: gelatin, glycerin, sunset yellow-orange dye (E 110), quinoline yellow (E 104);
• Excipients: acid-resistant coating of the capsule shell consists of the following components: eudragit, sodium lauryl sulfate, metacrylate copolymer (type A), propylene glycol, polysorbate 80, glycerol monostearate.

The medicine is available in a cardboard package containing blister strips, ten capsules in each strip. Additionally, the package contains instructions for use of the medicine.

The drug is produced in the amount of thirty pieces in each cardboard package.

Pharmacodynamics

The pharmacodynamics of the drug Tavipek are as follows:

• The drug is characterized by secretolytic, expectorant, mucolytic, epithelializing, anti-inflammatory, antimicrobial and immunostimulating properties.
• Secretolytic, mucolytic and expectorant action is due to the properties of the active component of lavender oil. Due to the use of this drug, sputum is removed from the upper and lower respiratory tract by increasing mucociliary clearance. As a result, the mucus present in the respiratory tract is liquefied, and the frequency of oscillation of the cilia of the epithelium of the bronchial mucosa increases. All of the above contributes to better release of excess sputum in the respiratory tract and cessation of coughing.
• The epithelializing properties of the drug consist of increasing the level of self-cleaning of the surface of the bronchial epithelium.
• The antimicrobial and anti-inflammatory action of the drug is possible due to the properties of lavender spike oil that enhance the activity of leukocytes. The use of Tavipek has a beneficial effect on increasing the phagocytic activity of leukocytes, which increases the immune properties of the patient's body, and also stimulates the antimicrobial and anti-inflammatory functioning of the cells of the immune system. The main component of lavender oil helps to reduce the activity of bacterial toxins: in staphylococci - alpha-hemolysin, in streptococci - streptolysin, and also helps to remove these substances from the body. The effect of the components of lavender spike oil allows you to suppress the development of most bacteria and fungi in the body (which include mycobacterium tuberculosis). At the same time, there is no disruption of the patient's intestinal microflora, which has a beneficial effect on improving immunity and the quality of the fight against the symptoms of the disease.
• The immunostimulating effect of the drug is due to the effect of the active components of the drug on cellular immunity and increased activity of immune cells. This process includes an increase in the phagocytic function of white blood cells - leukocytes.

Pharmacokinetics

The pharmacokinetics of the drug Tavipek is as follows:

• The active component of the drug is 1,8-cineole, which is labeled with an atom of lavender essential oil.
• The main component of lavender oil, cineole, is absorbed ninety-two percent into the walls of the gastrointestinal tract.
• The maximum content of the active component of lavender oil in blood plasma is observed after two and a half hours.
• The level of bioavailability of the drug does not decrease after the maximum time spent in the gastrointestinal tract.
• The highest amount of cineole in blood plasma is 72.4 ng/ml.
• The half-life of the drug from the body is considered to be a time period of one and a half hours.

Dosing and administration

Method of administration and dosage of the drug Tavipek:

• Adults are advised to take one to two capsules of the medicine orally three times a day.
• For children under twelve years of age, it is recommended to take one capsule three times a day.
• The capsules must be swallowed whole with a sufficient amount of water, without chewing the drug.
• The medicine is taken thirty minutes before meals.
• The maximum single use of the drug is two capsules.
• The maximum daily dose of the drug is six capsules.
• The duration of the course of treatment depends on the individual characteristics of the patient, the severity of the disease and the nature of the course of the disease. Before taking the drug, you must consult a specialist who determines the duration of use of Tavipek.

[ 3 ]

Use Tavipec during pregnancy

The use of Tavipek during pregnancy is not recommended. It is recommended to refrain from taking the drug during this period, as well as during lactation.

Contraindications

Contraindications to the use of the drug Tavipek are as follows:

• The presence of hypersensitivity to any of the substances in the drug.
• The period of pregnancy and breastfeeding in women.
• The medicine is not used in children and adolescents under twelve years of age.
• The drug is not recommended for use in gastric ulcer, hyperacid gastritis, acute hepatitis, pancreatitis and nephritis.

[ 1 ]

Side effects Tavipec

If you use Tavipek according to the instructions, then side effects are usually not observed.

The following side effects of the drug Tavipek have been identified:

• In rare cases, belching may occur.
• Also, at some points after taking the drug, nausea may occur for a short period of time.
• Vomiting may occur, as well as abdominal pain and dysgeusia.
• The development of allergic reactions to the drug cannot be ruled out. These include skin rashes, itching and redness of the skin.
• When exhaling after taking the medicine, the smell of lavender oil is felt for some time, which is not accompanied by unpleasant sensations.
• The drug has not been shown to affect the ability to drive vehicles or other mechanical means of transport.

[ 2 ]

Overdose

Overdose of Tavipek is not known, since there is no information on cases of such use of the drug.

There is no data in medical practice on the symptoms of overdose of lavender essential oil.

Nausea and some other gastrointestinal complaints, such as heartburn, may occur.

Interactions with other drugs

There are currently no known interactions between Tavipek and other drugs.

[ 4 ], [ 5 ]

Storage conditions

Storage conditions for the drug Tavipek are as follows:

• The medicine is recommended to be stored at room temperature not exceeding twenty-five degrees Celsius.
• The drug must be kept in a place protected from sunlight.
• Tavipek should be kept out of the reach of children.

Shelf life

The shelf life of the drug Tavipek is three years from the date of manufacture of the drug.

It is prohibited to use the medicine after the expiration date indicated on the package.